Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

M. Ladetto, F. Zallio, S. Vallet, I. Ricca, A. Cuttica, D. Caracciolo, P. Corradini, M. Astolfi, S. Sametti, F. Volpato, P. Bondesan, U. Vitolo, M. Boccadoro, A. Pileri, A. M. Gianni, C. Tarella

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The aim of this study was to investigate feasibility, tolerability and efficacy of rituximab-supplemented high-dose sequential chemotherapy (R-HDS) with peripheral blood progenitor cell autografting as frontline or salvage treatment in patients with advanced non-Hodgkin's lymphoma (NHL). Thirty-two patients have been treated: 14 at disease onset and 18 with relapsed or progressive disease. R-HDS regimens included six courses of rituximab. Rituximab was delivered either concurrently with high-dose chemotherapy to exploit the in vivo purging properties of the drug as well as at the end of the treatment plan to target minimal residual disease. All patients treated at disease onset completed their treatment with no life-threatening toxicity, while two toxic deaths due to severe bilateral pneumonia were observed among patients treated due to relapsed or refractory disease. Thirteen of 14 patients treated up-front achieved CR. Among pre-treated patients 10 of 18 achieved CR with better results in patients with relapsed (seven of eight) compared to progressive disease (three of 10). PCR analysis was carried out in indolent lymphoma patients: nine of nine follicular lymphomas and three of six CD5-positive NHL collected PCR-negative peripheral blood progenitor cell harvests. The results of this pilot study show that R-HDS is feasible and effective with acceptable toxicity when used at disease onset. In pre-treated patients this treatment also showed promising results, although the risk of severe infections needs to be considered.

Original languageEnglish
Pages (from-to)1941-1949
Number of pages9
JournalLeukemia
Volume15
Issue number12
Publication statusPublished - 2001

Fingerprint

Non-Hodgkin's Lymphoma
Immunotherapy
Drug Therapy
Blood Cells
Stem Cells
Rituximab
Salvage Therapy
Polymerase Chain Reaction
Follicular Lymphoma
Autologous Transplantation
Poisons
Residual Neoplasm
Lymphoma
Pneumonia
Therapeutics
Infection
Pharmaceutical Preparations

Keywords

  • Autologous transplantation
  • High-dose sequential chemotherapy (HDS)
  • Non-Hodgkin's lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Ladetto, M., Zallio, F., Vallet, S., Ricca, I., Cuttica, A., Caracciolo, D., ... Tarella, C. (2001). Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia, 15(12), 1941-1949.

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. / Ladetto, M.; Zallio, F.; Vallet, S.; Ricca, I.; Cuttica, A.; Caracciolo, D.; Corradini, P.; Astolfi, M.; Sametti, S.; Volpato, F.; Bondesan, P.; Vitolo, U.; Boccadoro, M.; Pileri, A.; Gianni, A. M.; Tarella, C.

In: Leukemia, Vol. 15, No. 12, 2001, p. 1941-1949.

Research output: Contribution to journalArticle

Ladetto, M, Zallio, F, Vallet, S, Ricca, I, Cuttica, A, Caracciolo, D, Corradini, P, Astolfi, M, Sametti, S, Volpato, F, Bondesan, P, Vitolo, U, Boccadoro, M, Pileri, A, Gianni, AM & Tarella, C 2001, 'Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma', Leukemia, vol. 15, no. 12, pp. 1941-1949.
Ladetto, M. ; Zallio, F. ; Vallet, S. ; Ricca, I. ; Cuttica, A. ; Caracciolo, D. ; Corradini, P. ; Astolfi, M. ; Sametti, S. ; Volpato, F. ; Bondesan, P. ; Vitolo, U. ; Boccadoro, M. ; Pileri, A. ; Gianni, A. M. ; Tarella, C. / Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. In: Leukemia. 2001 ; Vol. 15, No. 12. pp. 1941-1949.
@article{f46bb8c6d0fd4400bc3ab256aa64aaa8,
title = "Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma",
abstract = "The aim of this study was to investigate feasibility, tolerability and efficacy of rituximab-supplemented high-dose sequential chemotherapy (R-HDS) with peripheral blood progenitor cell autografting as frontline or salvage treatment in patients with advanced non-Hodgkin's lymphoma (NHL). Thirty-two patients have been treated: 14 at disease onset and 18 with relapsed or progressive disease. R-HDS regimens included six courses of rituximab. Rituximab was delivered either concurrently with high-dose chemotherapy to exploit the in vivo purging properties of the drug as well as at the end of the treatment plan to target minimal residual disease. All patients treated at disease onset completed their treatment with no life-threatening toxicity, while two toxic deaths due to severe bilateral pneumonia were observed among patients treated due to relapsed or refractory disease. Thirteen of 14 patients treated up-front achieved CR. Among pre-treated patients 10 of 18 achieved CR with better results in patients with relapsed (seven of eight) compared to progressive disease (three of 10). PCR analysis was carried out in indolent lymphoma patients: nine of nine follicular lymphomas and three of six CD5-positive NHL collected PCR-negative peripheral blood progenitor cell harvests. The results of this pilot study show that R-HDS is feasible and effective with acceptable toxicity when used at disease onset. In pre-treated patients this treatment also showed promising results, although the risk of severe infections needs to be considered.",
keywords = "Autologous transplantation, High-dose sequential chemotherapy (HDS), Non-Hodgkin's lymphoma, Rituximab",
author = "M. Ladetto and F. Zallio and S. Vallet and I. Ricca and A. Cuttica and D. Caracciolo and P. Corradini and M. Astolfi and S. Sametti and F. Volpato and P. Bondesan and U. Vitolo and M. Boccadoro and A. Pileri and Gianni, {A. M.} and C. Tarella",
year = "2001",
language = "English",
volume = "15",
pages = "1941--1949",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

AU - Ladetto, M.

AU - Zallio, F.

AU - Vallet, S.

AU - Ricca, I.

AU - Cuttica, A.

AU - Caracciolo, D.

AU - Corradini, P.

AU - Astolfi, M.

AU - Sametti, S.

AU - Volpato, F.

AU - Bondesan, P.

AU - Vitolo, U.

AU - Boccadoro, M.

AU - Pileri, A.

AU - Gianni, A. M.

AU - Tarella, C.

PY - 2001

Y1 - 2001

N2 - The aim of this study was to investigate feasibility, tolerability and efficacy of rituximab-supplemented high-dose sequential chemotherapy (R-HDS) with peripheral blood progenitor cell autografting as frontline or salvage treatment in patients with advanced non-Hodgkin's lymphoma (NHL). Thirty-two patients have been treated: 14 at disease onset and 18 with relapsed or progressive disease. R-HDS regimens included six courses of rituximab. Rituximab was delivered either concurrently with high-dose chemotherapy to exploit the in vivo purging properties of the drug as well as at the end of the treatment plan to target minimal residual disease. All patients treated at disease onset completed their treatment with no life-threatening toxicity, while two toxic deaths due to severe bilateral pneumonia were observed among patients treated due to relapsed or refractory disease. Thirteen of 14 patients treated up-front achieved CR. Among pre-treated patients 10 of 18 achieved CR with better results in patients with relapsed (seven of eight) compared to progressive disease (three of 10). PCR analysis was carried out in indolent lymphoma patients: nine of nine follicular lymphomas and three of six CD5-positive NHL collected PCR-negative peripheral blood progenitor cell harvests. The results of this pilot study show that R-HDS is feasible and effective with acceptable toxicity when used at disease onset. In pre-treated patients this treatment also showed promising results, although the risk of severe infections needs to be considered.

AB - The aim of this study was to investigate feasibility, tolerability and efficacy of rituximab-supplemented high-dose sequential chemotherapy (R-HDS) with peripheral blood progenitor cell autografting as frontline or salvage treatment in patients with advanced non-Hodgkin's lymphoma (NHL). Thirty-two patients have been treated: 14 at disease onset and 18 with relapsed or progressive disease. R-HDS regimens included six courses of rituximab. Rituximab was delivered either concurrently with high-dose chemotherapy to exploit the in vivo purging properties of the drug as well as at the end of the treatment plan to target minimal residual disease. All patients treated at disease onset completed their treatment with no life-threatening toxicity, while two toxic deaths due to severe bilateral pneumonia were observed among patients treated due to relapsed or refractory disease. Thirteen of 14 patients treated up-front achieved CR. Among pre-treated patients 10 of 18 achieved CR with better results in patients with relapsed (seven of eight) compared to progressive disease (three of 10). PCR analysis was carried out in indolent lymphoma patients: nine of nine follicular lymphomas and three of six CD5-positive NHL collected PCR-negative peripheral blood progenitor cell harvests. The results of this pilot study show that R-HDS is feasible and effective with acceptable toxicity when used at disease onset. In pre-treated patients this treatment also showed promising results, although the risk of severe infections needs to be considered.

KW - Autologous transplantation

KW - High-dose sequential chemotherapy (HDS)

KW - Non-Hodgkin's lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0035194993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035194993&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 1941

EP - 1949

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -